Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Last trade$9.25
Day change$0.00 (0.00%)
Day range$9.04 – $9.34
Volume407,404
Market cap$550M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$550.42M
Price / earnings
7.16×
Price / book
2.3×
Price / sales
3.72×
EV / sales
2.95×
EV / EBITDA
-40.57×
Profitability
Earnings per share
$1.29
Return on assets
24.51%
Return on equity
32.17%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
5.46×
Quick ratio
5.38×
Cash ratio
2.95×
Cash flow
Price / cash flow
14.21×
Price / free cash flow
14.38×
Free cash flow
$38.28M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZVRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$37.76M
$39.66M
$36.22M
$34.13M
$26.06M
$25.88M
$20.4M
$12.04M
Cost of revenue
$1.79M
$1.53M
$1.9M
$1.52M
$1.24M
$12.38M
$1.35M
$1.37M
Gross profit
$35.96M
$38.14M
$34.32M
$32.61M
$24.83M
$13.5M
$19.06M
$10.68M
Selling, general and administrative
$19.13M
$16.56M
$20.78M
$20.35M
$16.94M
$20.78M
$19.55M
$16.13M
Research and development
$4.94M
$4.49M
$4.39M
$2.62M
$3.43M
$3.43M
$3.26M
$8.35M
Total operating expenses
$24.38M
$21.36M
$25.49M
$23.29M
$20.68M
$84.54M
$24.42M
$26.09M
Operating income
$11.58M
$16.78M
$8.83M
$9.32M
$4.14M
-$71.04M
-$5.36M
-$15.42M
Interest expense
$0
$0
-$1.71M
-$1.95M
-$2.05M
-$2.01M
-$1.97M
-$2.19M
Income before taxes
$19.72M
$12.79M
$44.8M
$12.67M
-$977K
$76.91M
-$1.92M
-$20.37M
Income taxes
$510K
$4.04M
$6.91M
$501K
-$433K
$2.2M
$1.18M
$15.37M
Net income
$19.21M
$8.75M
$37.89M
$12.17M
-$544K
$74.71M
-$3.1M
-$35.74M
Net income attributable to common shareholders
$18.42M
$8.39M
$37.89M
$12.17M
-$544K
$67.91M
-$3.1M
-$35.74M
EBITDA
$11.96M
$17.14M
$9.2M
-$49.03M
$4.54M
-$10.68M
-$3.71M
-$13.77M
Basic earnings per share
$0.31
$0.14
$0.62
$0.22
-$0.01
$1.24
-$0.06
-$0.67
Diluted earnings per share
$0.26
$0.14
$0.60
$0.19
-$0.01
$1.21
-$0.06
-$0.67
Recent news
Company coverage with links to the original publishers.
Zevra Therapeutics (ZVRA) has a mean analyst price target of $25.25, suggesting 117.9% upside potential from its current $11.59 price. The stock has received a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions with a 21.8% increase over the past month. However, the article cautions that price targets should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.
Zevra Therapeutics reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.14, with revenues of $37.76 million exceeding expectations by 2.77%. The company has outperformed market estimates in four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Cronos Group is expected to report Q3 results on November 5, with projected earnings of $0.03 per share, down 57.1% year-over-year, though revenues are expected to grow 30.6%.
Zevra Therapeutics announced the presentation of long-term real-world data on MIPLYFFA (arimoclomol) for treating Niemann-Pick disease type C at the 2026 SSIEM Annual Symposium. Data from U.S. and German early access programs demonstrate sustained disease stabilization over up to 8 years with a consistent safety profile across diverse patient populations, including adults and children. The pivotal trial showed a 65% reduction in disease progression compared to placebo.
Zevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Marketing Authorization Application for arimoclomol to treat Niemann-Pick disease type C. The company plans to request a re-examination of the decision and continues supporting patient access through its Expanded Access Program.
XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.